The औषधम् Legacy
Building Tomorrow's Pharmaceutical Leader
5,000 Years of Healing Wisdom Meets Tomorrow's Innovation
OUR STORY
Chieron has established a strong presence in specific therapeutic segments such as cardiovascular and central nervous system (CNS). The company aspires to maintain its market leadership in these areas by continuously adding new molecules and expanding its global footprint. VNAI’s strategy includes global filings and approvals for all its products, enabling the company to engage with key customers worldwide. This approach has helped the company build a sustainable business model with a well-organized production and inventory planning system
CERTIFICATIONS
MANAGEMENT TEAM
Mr. Chandra Kumar Verma
MD & Chief Executive Officer
Post Graduate Diploma in Marketing & Operations, B.E. Chemical Engineering Mr. Verma brings over two decades of leadership experience in global API, intermediate, and formulation sales.
He has a proven track record in business development, strategic portfolio management, and operational excellence. Under his leadership, platforms have achieved sales revenues exceeding US$200M with gross margins over 60% and EBITDA above 35%. He has successfully scaled businesses from $110M to $200M and $80M to $150M within short timeframes. Mr. Verma has launched and commercialized over 300 APIs and 50 FDFs across regulated and emerging markets. His strategic vision has led to the execution of 5 M&A deals and over 50 strategic partnerships globally. He is known for conceptualizing BU-level strategies that have resulted in the creation of new businesses worth $100M with 85% gross margins.
Venkat "Srini" Srinivas
Chief of Staff & Chief Information Officer
Venkat “Srini” Srinivas is a transformational leader with 20+ years of experience driving strategic innovation and digital excellence across global pharmaceutical operations. As Chief of Staff & CIO, he orchestrates enterprise-wide alignment between technology, business objectives, and human capital to deliver measurable ROI and future-ready growth. Key Leadership Impact:
Spearheads digital transformation, HR strategy, and post-merger integration for the AP platform
Architect of technology-driven business models across manufacturing, QA, R&D, and global service delivery
Trusted advisor on strategic investments that bridge innovation with operational execution
CAREER HIGHLIGHTS
Previously held executive roles at Apotex and Cohance Lifesciences (Advent International portfolio), delivering cross-functional excellence in:
Enterprise IT strategy & digital roadmaps | M&A technology integration Operational transformation
Srini’s unique blend of technical expertise (BE Computer Science) and business acumen (MBA) empowers organizations to harness technology as a competitive differentiator. His executive education from premier institutions like NMIMS further strengthens his ability to lead at the intersection of people, processes, and technological innovation
As a key leader, Srini leads Digital Transformation, HR strategy, and post-M&A execution for the API platform, aligning technology, talent, and transactions to future-proof the business
LOCATIONS & GLOBAL PRESENCE
All over the globe including USA, all EU countries, UK, Japan, Korea, Bangladesh, Middle east countries, South American countries, and CIS countries.
MANUFACTURING FACILITIES
NELLORE PLANT
Address: Sy.No.69, Chandrapadiya village, Vinjamur mandal, SPSR Nellore dist, Andhra Pradesh -524228.
FACILITY DETAILS
Year Started: 1997
Location: Bollaram, Hyderabad
Function: Manufacturing of APIs
Installed Reactor Capacity: 82.8 KL
Area: Total area ~15,135 sq mtrs, Built-up area ~ 6,595 sq mtrs
Key Products Manufactured
APIs – Cetirizine Dihydrochloride, Amlodipine Besylate, Amlodipine Maleate, S – Amlodipine Besylate, Hydroxyzine HCL, Levocetirizine, Telmisartan, Raloxifene
Intermediates – Phthalimido amlodipine
Recent Expansion: Telmisartan block is under construction and it is commisioned by December 2024
PRODUCTION BLOCK-1 (PB-1)
8/2/293/82/564/A43/ 2nd Floor, Prasanth Towers, Road No 92, Jubilee Hills, Hyderabad, Telangana 500096
POLICIES
Glochem’s sustainability policies guide our actions across all business operations — from raw material sourcing to safe product delivery.
Approved by senior management and reviewed periodically, these policies ensure compliance with applicable laws, international standards, and the expectations of our stakeholders.
We regularly review our sustainability policies to reflect changing regulatory requirements, stakeholder expectations, and advancements in environmental and social performance.
Dr. Mayur Khunt
Chief Scientific Officer, Head of R&D / Regulatory Affairs
PhD in Organic Chemistry, Post Graduate Diploma in Patent Laws, 1 Year Certificate Senior Management (CEO) program at IIM KOZHIKODE
Dr. Khunt is a seasoned R&D leader with over 25 years of hands-on leadership experience across API R&D, Manufacturing, Techno-commercial strategy and global regulatory landscapes and has contributed to the development of 150+ pharmaceutical products, scale up 100+ molecules and has filled 40+ global patents, 10+ international Scientific articles publication & presentations and played a key role in securing PIV approvals through litigation with innovators.
From leading teams at Alembic, Dr. Reddy’s, Actavis (TEVA), Macleods, Hikal, Cohance (Advent Group), and currently working as management team at Audhataam platform.
His expertise spans complex product categories including chiral compounds, custom development, and multi-chain molecules, CRAMS business and speciality products like Electronic Chemicals (OLED), Semiconductor & Contrast Media products including High-Potent Active Ingredients (HPAI) & Peptide products. Dr. Khunt has led functions across project management, kilo lab, pilot plant, IPM, and regulatory affairs, and has collaborated with MNC innovators for custom product development.
Mr. TG Vinod
Chief Supply Chain Officer
Mr. T G Vinod has over 25 years of experience in Pharmaceutical Industry and has held various pivotal positions in various renowned Pharmaceutical companies. With a distinguished career spanning close to three decades, Mr. Vinod brings a wealth of expertise and strategic insight to the role of Supply Chain Management.
A Postgraduate in Operations Management from Symbiosis, Pune, Vinod is passionate about leading management teams to achieve new business heights. Earlier Vinod was associated with global pharmaceutical companies such as ZCL Chemicals Ltd., Dr Reddy’s Laboratories Ltd with a total span of over 23 years. His leadership was instrumental in steering the Supply Chain activities in his previous assignments, to support the sustainable supply chain and cost position. He has managed procurement spends exceeding $100Mn and built strong Supplier networks across India and China.
Mr Vinod’s appointment as Chief Supply Chain Officer marks a new chapter in his illustrious career, where he will contribute to the company’s vision and growth, leveraging his extensive experience and leadership acumen.
Mr. Bodhisatwa Ray.
Chief Financial Officer
Bodhisatwa Ray, known as Bodhi Ray among colleagues & peers, is aseasoned finance professional with over 20 years of experience acrossthe finance and accounting spectrum. With more than 12 years at Pfizer, Bodhi has spearheading strategic initiatives in areas such astaxation, accounting, treasury, insurance, digital transformation, FP and mergers and acquisitions. His leadership has played a crucial role incorporate restructuring, the establishment of R&D unit in India, creationof Centers of Excellence and managing joint ventures.
Prior to Pfizer, Bodhi held key roles at Dr. Reddy’s Laboratories and HSBC. He is a Chartered Accountant and an alumnus of IIM Ahmedabad
As CFO of Audhataam, Bodhi envisions building a robust financial framework that supports innovation and sustainable growth. He is committed to enhancing financial transparency, driving strategic value creation and fostering cross-functional collaboration.
With a passion for global business trends and a keen interest in investing, Bodhi brings a progressive and insightful approach to the leadership team.